Is it possible to get well without Johnson & Johnson (J&J)? The diversified health care giant operates in three segments through more than 250 operating companies located in some 60 countries. Its Medical Devices and Diagnostics division offers surgical equipment, monitoring devices, orthopedic products, and contact lenses, among other things. J&J's Pharmaceuticals division makes drugs for an array of ailments, such as neurological conditions, blood disorders, autoimmune diseases, and pain. Top sellers are psoriasis drug Remicade and anemia medication Procrit. Its Consumer business makes over-the-counter drugs and products for baby, skin, and oral care, as well as first aid and women's health.
Track this company’s financial condition.
View Company Report
Request Your Free Trial
| Income Statement | 2012 | 2011 | 2010 |
|---|---|---|---|
| Revenue | $67224.0 | $65030.0 | $61587.0 |
| Gross Profit | $45566.0 | $44670.0 | $42795.0 |
| Operating Income | $15869.0 | $16153.0 | $16527.0 |
| Net Income | $10853.0 | $9672.0 | $13334.0 |
| Diluted EPS | $3.86 | $3.49 | $4.78 |
| Cash Flow (mil) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Cash at the beginning of the year | $24542.0 | $19355.0 | $15810.0 |
| Net Operating Cash | $15396.0 | $14298.0 | $16385.0 |
| Net Investing Cash | $-4510.0 | $-4612.0 | $-7854.0 |
| Net Financing Cash | $-20562.0 | $-4452.0 | $-4980.0 |
| Net Change in Cash | $-9631.0 | $5187.0 | $3545.0 |
| Cash at end of the year | $14911.0 | $24542.0 | $19355.0 |
| Capital Expenditure | $-2934.0 | $-2893.0 | $-2384.0 |
| Assets (mil) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Current Assets | |||
| Cash | $14911.0 | $24542.0 | $19355.0 |
| Net Receivables | $11309.0 | $10581.0 | $9774.0 |
| Inventories | $7495.0 | $6285.0 | $5378.0 |
| Other Income Assets | $12401.0 | $12908.0 | $12800.0 |
| Asset Summary | |||
| Total Current Assets | $46116.0 | $54316.0 | $47307.0 |
| Net Fixed Assets | $16097.0 | $14739.0 | $14553.0 |
| Other Noncurrent Assets | $59134.0 | $44589.0 | $41048.0 |
| Total Assets | $121347.0 | $113644.0 | $102908.0 |
| Liabilities (mil) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $5831.0 | $5725.0 | $5623.0 |
| Short Term Debt | $4676.0 | $6658.0 | $7617.0 |
| Other Current Liabilities | $13755.0 | $10428.0 | $9832.0 |
| Liability Summary | |||
| Total Current Liabilities | $24262.0 | $22811.0 | $23072.0 |
| Long Term Debt | $11489.0 | $12969.0 | $9156.0 |
| Other Noncurrent Liabilities | $20770.0 | $20784.0 | $14101.0 |
| Total Liabilities | $56521.0 | $56564.0 | $46329.0 |
| Stakeholder's Equity (mil) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Equity | |||
| Preferred Stock Equity | $0.0 | $0.0 | $0.0 |
| Common Stock Equity | $64826.0 | $57080.0 | $56579.0 |
| Equity Summary | |||
| Total Equity | $64826.0 | $57080.0 | $56579.0 |
| Shares Outstanding | 2778.49 | 2730.85 | 2746.25 |